| Literature DB >> 32908547 |
Kusum Shrestha1,2, Anil Kumar Sah3, Neetu Singh4, Pramila Parajuli1, Rameshwar Adhikari2.
Abstract
INTRODUCTION: Group B streptococci (GBS) are globally recognized as one of the leading causes of neonatal sepsis and meningitis and is also known to cause adverse pregnancy outcomes such as stillbirths and miscarriages. Thus, detailed investigation of GBS in pregnant women has special significance in public health related researches.Entities:
Year: 2020 PMID: 32908547 PMCID: PMC7474781 DOI: 10.1155/2020/4046703
Source DB: PubMed Journal: J Trop Med ISSN: 1687-9686
Distribution of GBS in studied samples as well as typeable and nontypeable serotypes as observed in the GBS specimens.
| Suspected samples size | GBS positive (%) | PCR results | |
|---|---|---|---|
| Serotype positive (%) | Nontypeable (%) | ||
| 125 | 24 (19.2%) | 13 (54.25%) | 11 (45.5%) |
Figure 1Percentage distribution of GBS serotypes (Ia, Ib, II, and III) of S. agalactiae based on cps genes as indicated.
Figure 2Photograph showing the results of gel electrophoresis from (a) the confirmatory PCR assay targeting 780 bp atr gene (lane A: 100 bp DNA size marker; lane B: negative control (NC); lane C: positive control (PC); lanes D to F: clinical GBS samples M11, M14, and M21) and (b) the multiplex PCR assay for genotyping of GBS (see the text for amplicons size-serotype correlations).
Antimicrobial susceptibility pattern of GBS (n = 24) isolated from pregnant women.
| Name of antibiotics (mcg) | Sensitive (%) | Intermediate (%) | Resistant (%) |
|---|---|---|---|
| Penicillin (5) | 12 (50%) | — | 12 (50%) |
| Erythromycin (15) | 16 (66.67%) | — | 8 (33.33%) |
| Chloramphenicol (30) | 14 (58.3%) | 2 (8.3%) | 8 (33.33%) |
| Tetracycline (30) | — | — | 24 (100%) |
| Vancomycin (30) | 18 (75%) | — | 6 (25%) |
| Ertapenem (10) | — | — | 24 (100%) |
| Linezolid (30) | 24 (100%) | — | — |
| Levofloxacin (30) | 17 (70.8%) | 3 (12.5%) | 4 (16.7%) |
| Clindamycin (2) | 14 (58.33%) | — | 10 (41.67%) |
| Ceftriaxone (30) | 24 (100%) | — | — |
Distribution of GBS and serotypes on the basis of age, body mass, formal education level, parity, and gestational period.
| Age (years) | GBS positive (%) | Serotype positive |
| |||
|---|---|---|---|---|---|---|
| Ia | Ib | II | III | |||
| <19 ( | 1 (20%) | 0 | 0 | 0 | 0 | |
| 20–29 ( | 23 (22.77) | 1 | 1 | 3 | 8 | 0.148 |
| 30< ( | 0 | 0 | 0 | 0 | 0 | |
|
| ||||||
|
| ||||||
| Body mass (kg) | ||||||
| 41–50( | 1 (16.67%) | 1 | 0 | 0 | 0 | |
| 51–60( | 6 (15.79%) | 0 | 0 | 1 | 1 | |
| 61–70( | 11 (22.45%) | 0 | 0 | 2 | 5 | 0.794 |
| 71<( | 6 (18.75%) | 0 | 1 | 0 | 2 | |
|
| ||||||
|
| ||||||
| Formal education level | ||||||
| ≤secondary education examination ( | 16 (29.63%) | 1 | 0 | 3 | 4 | |
| +2 ( | 6 (14.28%) | 0 | 1 | 0 | 2 | 0.285 |
| Bachelor <( | 2 (6.89%) | 0 | 0 | 0 | 2 | |
|
| ||||||
|
| ||||||
| Parity | ||||||
| First ( | 14 (17.72%) | 1 | 1 | 3 | 5 | |
| Second ( | 8 (22.22%) | 0 | 0 | 0 | 2 | 0.893 |
| Third ( | 2 (20%) | 0 | 0 | 0 | 1 | |
|
| ||||||
|
| ||||||
| Gestational period | ||||||
| <36 ( | 7 (11.47%) | 0 | 1 | 2 | 2 | |
| >36 ( | 16 (25%) | 1 | 0 | 1 | 6 | 0.016 |
|
| ||||||